RNS Number : 9267A
BSF Enterprise PLC
17 April 2026

17 April 2026

# BSF Enterprise PLC

**Admission of Placing Shares**

Further to the announcement published on 02 April 2026, BSF Enterprise PLC ("**BSF**" or the "**Company**"), a leading innovator in tissue-engineered materials, announces that 38,500,000 ordinary shares of £0.01 each in the issued share capital of the Company ("**April 2026 Placing Shares**") have been admitted yesterday, 16 April 2026, to trading on the Main Market of the London Stock Exchange.

**April 2025 Placing - admission update**

Further to the announcement published on 28 April 2025 in relation to the placing of 4,725,000 new ordinary shares in the Company at 3 pence per share (the "**April 2025 Placing Shares**"), the Company has instructed new advisers, Bowsprit Partners, to arrange the application for the April 2025 Placing Shares to be admitted to listing on the Official List and to trading on the Main Market of the London Stock Exchange ("**Admission**").

The April 2025 Placing Shares were issued on 15 May 2025 pursuant to the placing announced on 28 April 2025. It is expected that Admission will become effective and that dealings in those shares are expected to commence at 8.00 a.m. on 21 April 2026.

**Correction to Broker Warrants disclosure**

The Company corrects an error in its announcement of 2 April 2026. The number of Broker Warrants was stated as 23,100. The correct number is 2,310,000.

**Total voting rights**

Following Admission, the total number of ordinary shares and voting rights in the Company will be 166,874,437. The total number of ordinary shares in issue is unchanged from the announcement dated 2 April 2026, as the April 2025 Placing Shares were already issued and included in that figure.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

**END**

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:

https://bsfenterprise.com/link/y0zqZr

**For further** enquiries, please visit www.bsfenterprise.com or contact:

| | |
|---|---|
| **BSF Enterprise PLC**<br>Geoff Baker - Chairman<br>Che Connon - CEO & Director<br><br>We encourage all investors to share questions on this announcement via our investor website. | https://bsfenterprise.com/s/a1f22b |

| | |
|---|---|
| **Bowsprit Partners**<br>John Treacy<br>James Sheehan | <br>+44 (0)203 883 4430 |
| **Shard Capital (Broker)**<br>Damon Heath<br>Isabella Pierre | <br>(0)20 4530 6926<br>(0)20 4530 6928 |
| *ISIN of the Ordinary Shares*<br>*is GB00BHNBDQ51.*<br>*SEDOL Code is BHNBDQ5.* | |

**Subscribe to our news alert service:** https://bsfenterprise.com/s/bb9f43

**About BSF Enterprise PLC**

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCZZGMDNNDGVZG